Clinical Trials Browser

Phase 3 × B-cell Malignancies × tislelizumab × Clear all

NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Phase 3 Active not recruiting

B-cell Malignancies